Ginkgo Investor Conference Presentation Deck
Each new cell program can accelerate adoption within new markets
and lead to further sales with existing customers
# of Active Programs/ Yr (Customer X)
12
10
8
2
0
Ability to grow significantly within existing
customer accounts
Major Program
Minor Program
Proof of Concept
Year 1
Year 2
Year 3
Year 4
Year 5
(1) Major programs typically incur well over $500K of annual R&D spending, minor programs are typically smaller add-on programs that have less
than $500K of annual R&D spend, proof-of-concept programs are typically small programs that are often set up as a business development effort
Early proof points within an industry
can lead to follow-on demand
moderna
[CONFIDENTIAL]
Optimizing pDNA production
for another nucleic acid
vaccine company
[CONFIDENTIAL]
In advanced discussions with
leading pharmaceutical
contract manufacturer
RAYMOND JAMES | JUNE 2021
GINKGO BIOWORKS
29View entire presentation